Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer

A significant fraction of non-small cell lung cancer (NSCLC) cases are due to oncogenic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Anti-EGFR antibodies have shown limited clinical benefit for NSCLC, whereas tyrosine kinase inhibitors (TKIs) are effective,...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Brian J., Guldenpfennig, Caitlyn, Guan, Yue, Winkler, Calvin, Beecher, Margaret, Beedy, Michaela, Berendzen, Ashley F., Ma, Lixin, Daniels, Mark A., Burke, Donald H., Porciani, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589377/
https://www.ncbi.nlm.nih.gov/pubmed/37869258
http://dx.doi.org/10.1016/j.omtn.2023.102046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589377/
https://www.ncbi.nlm.nih.gov/pubmed/37869258
http://dx.doi.org/10.1016/j.omtn.2023.102046

Ejemplares similares